Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.8)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 7, October, p. 1095–1099

doi: 10.17219/acem/66837

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Oxidative stress parameters in patients with prostate cancer, benign prostatic hyperplasia and asymptomatic inflammatory prostatitis: A prospective controlled study

Engin Kaya1,A,B,C,D,E,F, Yasar Ozgok2,F, Murat Zor3,D,E, Ayse Eken4,C, Selahattin Bedir2,E,F, Onur Erdem4,B,C, Turgay Ebiloglu5,B,C, Giray Ergin6,A,B

1 Department of Urology, Gülhane Askeri Tıp Akademisi (GATA), Ankara, Turkey

2 Urology Department, Medical Faculty, Gülhane Military Medical Academy (GMMA), Ankara, Turkey

3 Department of Urology, Gülhane Askeri Tıp Akademisi Haydarpasa Research Center, Istanbul, Turkey

4 Pharmacology Department, Medical Faculty, Gülhane Military Medical Academy (GMMA), Ankara, Turkey

5 Urology Department, Etimesgut Military Hospital, Turkey

6 Urology Department, Agrı Military Hospital, Turkey

Abstract

Background. The imbalance between oxidant and reductant mechanisms creates a nidus for the etiopathogenesis of several diseases. In this study, we aimed to compare the oxidative stress (OS) parameters in patients who were diagnosed with prostate cancer (pCa), benign prostatic hyperplasia (BPH) or asymptomatic inflammatory prostatitis (AIP), according to the histopathologic examination of transrectal ultrasonographic prostate biopsy and transurethral prostate resection specimens.
Objectives. In this study, we aimed to compare oxidative stress between histologically proven prostate cancer, hyperplasia and prostatitis.
Material and Methods. According to histopathologic examinations, 97 patients were divided into 3 study groups: group 1: pCa (n = 30), group 2: BPH (n = 41), and group 3: AIP (n = 26). Finally, 30 patients were enrolled in a control group. MDA levels, CuZn-SOD, Se-GPx, CAT activities, and trace element levels were evaluated.
Results. A statistically significant difference between prostate cancer and other groups were documented in terms of MDA activity. Contrary to AIP, a statistically significant difference has also been encountered between BPH and the control group. Decreased CuZn-SOD enzyme levels were found in PCa and BPH patients without statistical significance. Increased CAT activity was also documented in PCa, BPH and AIP patients. No significant difference in GPX activity was documented between the groups, except BPH and control group. Trace element levels were low in the patients with prostate cancer and BPH when compared with the control group.
Conclusion. Despite the data regarding OS in PCa patients, there is a paucity of data regarding BPH and especially AIP patients. Our study revealed obvious oxidative stress in BPH and PCa patients as opposed to AIP. Assessing the oxidative stress in these patients may assist in the future prevention, diagnosis and also treatment. However, the question whether the presence of OS-related parameters and drugs could be used for the diagnosis or management of prostatic diseases, needs to be addressed in future larger and better studies with a more rational basis.

Key words

prostate cancer, oxidative stress, chronic prostatitis, benign prostatic hyperplasia, prostate biopsy

References (37)

  1. Paschos A, Pandya R, Duivenvoorden WC, Pinthus JH. Oxidative stress in prostate cancer: Changing research concepts towards a novel paradigm for prevention and therapeutics. Prostate Cancer and Prostatic Diseases. 2013;16(3):217–225.
  2. Khandrika L, Kumar B, Koul S, Maroni P, Koul HK. Oxidative stress in prostate cancer. Cancer Lett. 2009;18;282(2):125–136.
  3. Minciullo PL, Inferrera A, Navarra M, Calapai G, Magno C, Gangemi S. Oxidative stress in benign prostatic hyperplasia: A systematic review. Urol Int. 2014 [Epub ahead of print].
  4. Eken A, Aydın A, Erdem O, Akay C, Sayal A, Somuncu I. Induced antioxidant activity in hospital staff occupationally exposed to ionizing radiation. Int J Radiat Biol. 2012;88(9):648–653.
  5. Tüzün A, Değertekin B, Yeşilova Z, et al. Plasma MDA levels, GSH-Px activities and nitrite/nitrate levels in patients with familial Mediterranean fever. JCAM 2010;1(1):1–5.
  6. Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121–126.
  7. Merendino RA, Salvo F, Saija A, et al. Malondialdehyde in benign prostate hypertrophy: A useful marker? Mediat Inflamm. 2003;12(2):127–128.
  8. Meagher EA, FitzGerald GA. Indices of lipid peroxidation in vivo: Strengths and limitations. Free Radic Biol Med. 2000;28(12):1745–1750.
  9. Ray G, Batra S, Shukla NK, et al. Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast Cancer Res Treat. 2000;59(2):163–170.
  10. Senthil K, Aranganathan S, Nalini N. Evidence of oxidative stress in the circulation of ovarian cancer patients. Clin Chim Acta. 2004;339(1-2):27–32.
  11. Olinski R, Zastawny TH, Foksinski M, Barecki A, Dizdaroglu M. DNA base modifications and antioxidant enzyme activities in human benign prostatic hyperplasia. Free Radic Biol Med. 1995;18(4):807–813.
  12. Doğru-Abbasoğlu S, Aykaç-Toker G, Koçak T, Unlüer E, Uysal M. Antioxidant enzyme activities and lipid peroxides in the plasma of patients with benign prostatic hyperplasia or prostate cancer are not predictive. J Cancer Res Clin Oncol. 1999;125(7):402–404.
  13. Almushatat AS, Talwar D, McArdle PA, et al. Vitamin antioxidants, lipid peroxidation and the systemic inflammatory response in patients with prostate cancer. Int J Cancer. 2006;118(4):1051–1053.
  14. Yilmaz MI, Saglam K, Sonmez A, et al. Antioxidant system activation in prostate cancer. Biol Trace Elem Res. 2004;98(1):13–19.
  15. Arsova-Sarafinovska Z, Eken A, Matevska N, et al. Increased oxidative/nitrosative stress and decreased antioxidant enzyme activities in prostate cancer. Clin Biochem. 2009;42(12):1228–1235.
  16. Surapaneni KM, Venkata GR. Lipid peroxidation and antioxidant status in patients with carcinoma of prostate. Indian J Physiol Pharmacol. 2006;50(4):350–354.
  17. Yossepowitch O, Pinchuk I, Gur U, Neumann A, Lichtenberg D, Baniel J. Advanced but not localized prostate cancer is associated with increased oxidative stress. J Urol. 2007;178(4):1238–1244.
  18. Jung K, Seidel B, Rudolph B, et al. Antioxidant enzymes in malignant prostate cell lines and in primary cultured prostatic cells. Free Radic Biol Med. 1997;23(1):127–133.
  19. Gaté L, Paul J, Ba GN, Tew KD, Tapiero H. Oxidative stress induced in pathologies: The role of antioxidants. Biomed Pharmacother. 1999;53(4):169–180.
  20. Kumaraguruparan R, Subapriya R, Kabalimoorthy J, Nagini S. Antioxidant profile in the circulation of patients with fibroadenoma and adenocarcinoma of the breast. Clin Biochem. 2002;35(4):275–279.
  21. Aydin A, Arsova-Sarafinovska Z, Sayal A, et al. Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia. Clin Biochem. 2006;39(2):176–179.
  22. Zhou JF, Xiao WQ, Zheng YC, Dong J, Zhang SM. Increased oxidative stress and oxidative damage associated with chronic bacterial prostatitis. Asian J Androl. 2006;8(3):317–323.
  23. Baker AM, Oberley LW, Cohen MB. Expression of antioxidant enzymes in human prostatic adenocarcinoma. Prostate. 1997;1;32(4):229–233.
  24. Battisti V, Maders LD, Bagatini MD, et al. Oxidative stress and antioxidant status in prostate cancer patients: Relation to Gleason score, treatment and bone metastasis. Biomed Pharmacother. 2011;65(7):516–524.
  25. Biri H, Oztürk HS, Kaçmaz M, Karaca K, Tokuçoğlu H, Durak I. Activities of DNA turnover and free radical metabolizing enzymes in cancerous human prostate tissue. Cancer Invest. 1999;17(5):314–319.
  26. Sapota A, Darago A, Taczalski J, Kilanowicz A. Disturbed homeostasis of zinc and other essential elements in the prostate gland dependent on the character of pathological lesions. Biometals. 2009;22(6):1041–1049.
  27. Yan M, Song Y, Wong CP, Hardin K, Ho E. Zinc deficiency alters DNA damage response genes in normal human prostate epithelial cells. J Nutr. 2008;138(4):667–673.
  28. Christudoss P, Selvakumar R, Fleming JJ, Gopalakrishnan G. Zinc status of patients with benign prostatic hyperplasia and prostate carcinoma. Indian J Urol. 201;27(1):14–18.
  29. Malm J, Hellman J, Hogg P, Lilja H. Enzymatic action of prostate-specific antigen (PSA or hK3): Substrate specificity and regulation by Zn(2+), a tight-binding inhibitor. Prostate. 2000;1;45(2):132–139.
  30. Redman C, Scott JA, Baines AT, et al. Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett. 1998;125(1-2):103–110.
  31. Redman C, Xu MJ, Peng YM, et al. Involvement of polyamines in selenomethionine induced apoptosis and mitotic alterations in human tumor cells. Carcinogenesis. 1997;18(6):1195–1202.
  32. Griffin AC. Role of selenium in the chemoprevention of cancer. Adv Cancer Res. 1979;29:419–442.
  33. Waters DJ, Shen S, Cooley DM, et al. Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate. J Natl Cancer Inst. 2003;95(3):237–241.
  34. Arshad MA, Bhadra S, Cohen RM, Subbiah MT. Plasma lipoprotein peroxidation potential: A test to evaluate individual susceptibility to peroxidation. Clin Chem. 1991;37(10):1756–1758.
  35. Brooks JD, Metter EJ, Chan DW, et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol. 2001;166(6):2034–2038.
  36. Lipsky K, Zigeuner R, Zischka M, et al. Selenium levels of patients with newly diagnosed prostate cancer compared with control group. Urology. 2004;63(5):912–916.
  37. Muecke R, Klotz T, Giedl J, et al. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH. Acta Oncol. 2009;48(3):452–456.
© Wroclaw Medical University